NantCell, Inc. has exercised its option to enter into licensing agreement with GlobeImmune, Inc. for GI-6100 program targeting the MUC1 protein. Under the terms of the agreement, GlobeImmune is entitled to receive payments on the achievement of certain product development and commercialization milestones and royalties based on net sales of products by NantCell or its affiliates or sublicensees. Following the agreement, NantCell intends to combine GI-6207 and GI-6301 with GI-4000 and other agents in a number of trials. Concurrently, NantCell has entered into licensing agreement with GlobeImmune for exclusive worldwide rights to GI-4000. Concurrently, NantCell has entered into licensing agreement with GlobeImmune for GI-6207 and GI-6301.